Daiichi Sankyo Exercises Option With Aussie Biotech Biota For Second-Gen Flu Drug
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Daiichi Sankyo has exercised its option to manufacture and market in Japan its second-generation influenza long-acting neuraminidase inhibitor CS-8958, co-owned with Autralian biotech Biota. The agreement is contingent upon successful completion of pivotal Phase III trials and approval, Biota announced March 30
You may also be interested in...
Daiichi Sankyo Lifts FY2009 Profit Forecasts, Submits NDA For Flu Inhaler Laninamivir
Daiichi Sankyo Jan. 29 lifted profit estimations for fiscal year 2009, citing favorable exchange rates for the Indian rupee against the U.S. dollar, as well as improvements in subsidiary Ranbaxy Laboratories
Daiichi Sankyo Lifts FY2009 Profit Forecasts, Submits NDA For Flu Inhaler Laninamivir
Daiichi Sankyo Jan. 29 lifted profit estimations for fiscal year 2009, citing favorable exchange rates for the Indian rupee against the U.S. dollar, as well as improvements in subsidiary Ranbaxy Laboratories
Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo
PERTH, Australia - Australian biotech Biota Holdings announced positive Phase III results of its Asian clinical trials for second-generation influenza treatment CS-8958, co-developed and co-owned with Daiichi Sankyo
Need a specific report? 1000+ reports available
Buy Reports